1-3 of 3
Emmanuelle di Tomaso
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Free
Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3507–3520.
https://doi.org/10.1158/1078-0432.CCR-13-2769
Published: 01 July 2014
View article titled, Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Open the PDF for Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Free
Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhua Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, Joseph T. Beck, Emmanuelle Di Tomaso, David W. Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1935–1945.
https://doi.org/10.1158/1078-0432.CCR-13-1070
Published: 31 March 2014
View article titled, Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Open the PDF for Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value

Free
Andrew X. Zhu, Dan G. Duda, Marek Ancukiewicz, Emmanuelle di Tomaso, Jeffrey W. Clark, Rebecca Miksad, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 918–927.
https://doi.org/10.1158/1078-0432.CCR-10-0515
Published: 15 February 2011
View article titled, Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
Open the PDF for Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value in another window
Includes: Supplementary data